Impact of Timing of Pharmacodynamic Assessments on Measures of Platelet Reactivity in Patients Undergoing Percutaneous Coronary Intervention Treated With Cangrelor
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Change in platelet reactivity
研究概览
简要总结
This study is assessing the impact of timing of PD assessments on measures of platelet reactivity in patients undergoing PCI treated with cangrelor.
详细描述
Cangrelor is characterized by reversible binding to the P2Y12 receptor and is promptly inactivated through dephosphorylation by ectonucleotidase leading to its very short plasma half-life. Consequently the timing at which PD assessments are performed after blood sample collection may impact measures of platelet reactivity in patients treated with cangrelor. We therefore hypothesize that measures of platelet inhibitory effects observed in cangrelor treated patients will reduce with time following blood sampling.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years old
- •CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI and treated with cangrelor per standard of care.
- •Treated with aspirin prior to the PCI procedure per standard of care
排除标准
- •Treatment with an oral P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) within past 10 days
- •Treatment with oral anticoagulation (vitamin K antagonist, dabigatran, apixaban, rivaroxiban) within past 3 days
- •Treatment with a glycoprotein IIb/IIIa inhibitor during PCI
- •Fibrinolytics within 48 hours
- •Known hemoglobin<10 gm/dL
- •Known platelet count <80x106/mL
- •Active bleeding or hemodynamic instability
- •Known end stage renal disease on hemodialysis
- •Known severe hepatic dysfunction
结局指标
主要结局
Change in platelet reactivity
时间窗: wiithin 30 min, 1 hour, 2 hours, and 4 hours of blood sampling
measure of change platelet reactivity at time points
次要结局
未报告次要终点